Salarius Pharmaceuticals, Inc.(SLRX)Earnings, Financials & Key Ratios
SLRX•NASDAQ
$0.74
$697790 mkt cap·Price updated May 1, 2026
AboutSalarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.Show more
- Revenue$0
- EBITDA-$6M+55.5%
- Net Income-$6M+55.5%
- EPS (Diluted)-86.85-152268.4%
- ROE-164.02%-2.5%
- Debt/Equity0.15+167.9%
SLRX Key Insights
Salarius Pharmaceuticals, Inc. (SLRX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Share count reduced 70.5% through buybacks
- ✓Trading at only 0.0x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Weak momentum: RS Rating 7 (bottom 7%)
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
SLRX Price & Volume
Salarius Pharmaceuticals, Inc. (SLRX) stock price & volume — 10-year historical chart
Loading chart...
SLRX Growth Metrics
Salarius Pharmaceuticals, Inc. (SLRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-0.22%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM61.9%
Return on Capital
10 Years-94.69%
5 Years-110.52%
3 Years-154.31%
Last Year-168.68%
SLRX Peer Comparison
Salarius Pharmaceuticals, Inc. (SLRX) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 5.66B | 27.84 | -10.20 | -47.07% | 0.00 | |||
 KROS | 438.1M | 11.77 | 5.12 | 67.75% | 35.65% | 14.25% | 24.19% | 0.06 |
 TPVG | 221.89M | 5.48 | 4.49 | 36.55% | 50.62% | 14.02% | 1.33 | |
 AGEN | 147.29M | 4.17 | -1226.47 | 10.37% | 0.1% | |||
 ALDX | 103.48M | 1.72 | -1.83 | -87.71% | 0.22 | |||
 RVMD | 29B | 147.21 | -24.74 | -69.35% | 0.10 | |||
 AUPH | 2.12B | 16.04 | 7.75 | 20.38% | 101.47% | 49.4% | 6.38% | 0.13 |
 SYRS | 5.37K | 0.00 | 0 | -33.23% | -253.41% | -227.95% | 3.73 |
Compare SLRX vs Peers
Salarius Pharmaceuticals, Inc. (SLRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SLRX Income Statement
Salarius Pharmaceuticals, Inc. (SLRX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 1.01M | 1.27M | 838.14K | 3.47M | 5.23M | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | 26.11% | -34.24% | 313.42% | 51.03% | -100% | - | - | - | - |
| Cost of Goods Sold | 662.75K | 506.53K | 430.75K | 0 | 0 | 0 | 0 | 0 | 0 | 1.11K |
| COGS % of Revenue | 65.58% | 39.74% | 51.39% | - | - | - | - | - | - | - |
| Gross Profit | 347.92K▲ 0% | 767.97K▲ 120.7% | 407.39K▼ 47.0% | 3.47M▲ 750.5% | 5.23M▲ 51.0% | 0▼ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -1.11K▲ 0% |
| Gross Margin % | 34.42% | 60.26% | 48.61% | 100% | 100% | - | - | - | - | - |
| Gross Profit Growth % | 797.49% | 120.73% | -46.95% | 750.55% | 51.03% | -100% | - | - | - | - |
| Operating Expenses | 40.23M | 35.49M | 22.48M | 11.73M | 13.02M | 12.81M | 31.84M | 12.89M | 5.73M | 5.07M |
| OpEx % of Revenue | 3980.97% | 2784.91% | 2682.32% | 338.53% | 248.78% | - | - | - | - | - |
| Selling, General & Admin | 19.86M | 18.5M | 10.57M | 7.71M | 6.11M | 6.1M | 7.14M | 5.72M | 4.96M | 4.64M |
| SG&A % of Revenue | 1964.65% | 1451.84% | 1261.52% | 222.54% | 116.67% | - | - | - | - | - |
| Research & Development | 20.38M | 16.99M | 11.91M | 4.02M | 6.91M | 8.55M | 15.84M | 7.17M | 770.03K | 429.08K |
| R&D % of Revenue | 2016.32% | 1333.07% | 1420.8% | 115.99% | 132.11% | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | -1.84M | 8.87M | 0 | 0 | 0 |
| Operating Income | -39.89M▲ 0% | -34.73M▲ 12.9% | -22.07M▲ 36.4% | -8.27M▲ 62.6% | -7.79M▲ 5.8% | -12.81M▼ 64.6% | -31.84M▼ 148.5% | -12.89M▲ 59.5% | -5.73M▲ 55.5% | -5.07M▲ 0% |
| Operating Margin % | -3946.54% | -2724.65% | -2633.71% | -238.53% | -148.78% | - | - | - | - | - |
| Operating Income Growth % | -36.54% | 12.94% | 36.43% | 62.56% | 5.79% | -64.56% | -148.51% | 59.5% | 55.53% | - |
| EBITDA | -39.61M | -34.4M | -21.85M | -8.14M | -7.77M | -12.79M | -31.83M | -12.88M | -5.73M | -5.06M |
| EBITDA Margin % | -3919.11% | -2699.18% | -2606.49% | -234.85% | -148.44% | - | - | - | - | - |
| EBITDA Growth % | -35.82% | 13.15% | 36.5% | 62.75% | 4.54% | -64.69% | -148.83% | 59.53% | 55.53% | 2.84% |
| D&A (Non-Cash Add-back) | 277.23K | 324.55K | 228.16K | 127.41K | 18.06K | 19.18K | 6.68K | 10.05K | 4.42K | 4.42K |
| EBIT | -39.89M | -34.73M | -22.07M | -8.26M | -7.61M | -12.81M | -22.98M | -12.89M | -5.73M | -5.05M |
| Net Interest Income | 393.11K | 291.96K | 152.01K | 15.65K | -3.05K | 0 | 219 | 352.25K | 158.54K | 63.34K |
| Interest Income | 393.11K | 291.96K | 152.01K | 15.65K | 0 | 0 | 219 | 352.25K | 158.54K | 63.34K |
| Interest Expense | 0 | 0 | 0 | 0 | 3.05K | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 393.11K | 291.96K | 152.01K | 1.33M | 434.09K | 44.69K | 233.18K | 352.25K | 158.54K | 63.34K |
| Pretax Income | -39.49M▲ 0% | -34.43M▲ 12.8% | -21.92M▲ 36.3% | -6.94M▲ 68.4% | -7.35M▼ 6.0% | -12.77M▼ 73.7% | -31.61M▼ 147.6% | -12.54M▲ 60.3% | -5.58M▲ 55.5% | -5M▲ 0% |
| Pretax Margin % | -3907.65% | -2701.74% | -2615.57% | -200.18% | -140.49% | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -39.49M▲ 0% | -34.43M▲ 12.8% | -21.92M▲ 36.3% | -6.94M▲ 68.4% | -7.35M▼ 6.0% | -12.77M▼ 73.7% | -31.61M▼ 147.6% | -12.54M▲ 60.3% | -5.58M▲ 55.5% | -5M▲ 0% |
| Net Margin % | -3907.65% | -2701.74% | -2615.57% | -200.18% | -140.49% | - | - | - | - | - |
| Net Income Growth % | -35.52% | 12.81% | 36.33% | 68.36% | -6% | -73.66% | -147.55% | 60.32% | 55.55% | -0.22% |
| Net Income (Continuing) | -39.49M | -34.43M | -21.92M | -6.94M | -7.35M | -12.77M | -31.61M | -12.54M | -5.58M | -5M |
| Discontinued Operations | 0 | 0 | 0 | 1.83K | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -182250.00▲ 0% | -149250.00▲ 18.1% | -91500.00▲ 38.7% | -6360.00▲ 93.0% | -1500.00▲ 76.4% | -930.00▲ 38.0% | -221.55▲ 76.2% | -0.06▲ 100.0% | -86.85▼ 152268.4% | -10.39▲ 0% |
| EPS Growth % | -836.11% | 18.11% | 38.69% | 93.05% | 76.42% | 38% | 76.18% | 99.97% | -152268.42% | 61.9% |
| EPS (Basic) | -182250.00 | -149250.00 | -91500.00 | -6360.00 | -1500.00 | -930.00 | -221.55 | -0.06 | -86.85 | - |
| Diluted Shares Outstanding | 1.09M | 1.16M | 1.21M | 1.09K | 5.22K | 13.86K | 142.34K | 218.73K | 64.47K | 481.59K |
| Basic Shares Outstanding | 1.09M | 1.16M | 1.21M | 1.09K | 5.22K | 13.8K | 142.34K | 218.73K | 64.47K | 481.59K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
SLRX Balance Sheet
Salarius Pharmaceuticals, Inc. (SLRX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 62.47M | 34.54M | 10.32M | 4.69M | 15.8M | 30.16M | 14.52M | 6.52M | 2.99M | 6.06M |
| Cash & Short-Term Investments | 61.07M | 33.32M | 9.83M | 3.74M | 11.12M | 29.21M | 12.11M | 5.9M | 2.43M | 4.81M |
| Cash Only | 22.42M | 19.19M | 9.83M | 3.74M | 11.12M | 29.21M | 12.11M | 5.9M | 2.43M | 4.81M |
| Short-Term Investments | 38.66M | 14.13M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 12.18K | 10.38K | 9.94K | 0 | 3.86M | 0 | 1.61M | 0 | 0 | 0 |
| Days Sales Outstanding | 4.4 | 2.97 | 4.33 | - | 268.94 | - | - | - | - | - |
| Inventory | 454.13K | 431.89K | 186.92K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 250.11 | 311.22 | 158.39 | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 767.56K | 249.09K | 0 | 137.78K | 172.99K | 167.58K | 151.27K | 221.58K | 1.26M |
| Total Non-Current Assets | 747.71K | 457.63K | 74.46K | 9.2M | 9.14M | 10.67M | 130.5K | 66.85K | 35.41K | 32.09K |
| Property, Plant & Equipment | 556.32K | 331.04K | 74K | 25.02K | 22.64K | 7.88K | 0 | 0 | 0 | 0 |
| Fixed Asset Turnover | 1.82x | 3.85x | 11.33x | 138.51x | 231.16x | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 8.87M | 8.87M | 8.87M | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 66.4K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 1.61M | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 191.4K | 60.2K | 460 | 308.67K | 247.11K | 185.99K | 130.5K | 66.85K | 35.41K | 135.01K |
| Total Assets | 63.21M▲ 0% | 34.99M▼ 44.6% | 10.39M▼ 70.3% | 13.89M▲ 33.7% | 24.93M▲ 79.4% | 40.83M▲ 63.8% | 14.65M▼ 64.1% | 6.59M▼ 55.0% | 3.02M▼ 54.1% | 6.1M▲ 0% |
| Asset Turnover | 0.02x | 0.04x | 0.08x | 0.25x | 0.21x | - | - | - | - | 0.00x |
| Asset Growth % | -33.51% | -44.64% | -70.31% | 33.73% | 79.44% | 63.78% | -64.12% | -55.04% | -54.1% | -109.02% |
| Total Current Liabilities | 3.89M | 5.85M | 5.02M | 3.31M | 2.77M | 2.11M | 4.27M | 1.3M | 1.51M | 1.1M |
| Accounts Payable | 1.19M | 2M | 342.53K | 1.79M | 1.85M | 1.54M | 2.86M | 602.85K | 936.99K | 1.1M |
| Days Payables Outstanding | 656.58 | 1.44K | 290.25 | - | - | - | - | - | - | 412.01K |
| Short-Term Debt | 0 | 0 | 0 | 502.33K | 477.03K | 0 | 0 | 289.64K | 221.87K | 0 |
| Deferred Revenue (Current) | 88K | 72.19K | 0 | 541.7K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.16M | 2.9M | 3.91M | 317.76K | 59.21K | 0 | 0 | 0 | 0 | 0 |
| Current Ratio | 16.06x | 5.91x | 2.06x | 1.42x | 5.70x | 14.29x | 3.40x | 5.02x | 1.98x | 1.98x |
| Quick Ratio | 15.94x | 5.83x | 2.02x | 1.42x | 5.70x | 14.29x | 3.40x | 5.02x | 1.98x | 1.98x |
| Cash Conversion Cycle | -402.07 | -1.13K | -127.53 | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 8.4K | 39.21K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 744.78K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 8.4K | 39.21K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.49M |
| Total Liabilities | 3.9M | 5.89M | 1.11M | 3.31M | 2.77M | 2.11M | 4.27M | 1.3M | 1.51M | 1.85M |
| Total Debt | 0 | 0 | 0 | 502.33K | 477.03K | 0 | 0 | 289.64K | 221.87K | 0 |
| Net Debt | -22.42M | -19.19M | -9.83M | -3.24M | -10.64M | -29.21M | -12.11M | -5.61M | -2.21M | -4.81M |
| Debt / Equity | - | - | - | 0.05x | 0.02x | - | - | 0.05x | 0.15x | 0.15x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.95x |
| Interest Coverage | - | - | - | - | -2555.41x | - | - | - | - | - |
| Total Equity | 59.32M▲ 0% | 29.11M▼ 50.9% | 9.28M▼ 68.1% | 10.58M▲ 14.0% | 22.16M▲ 109.4% | 38.72M▲ 74.7% | 10.38M▼ 73.2% | 5.29M▼ 49.1% | 1.51M▼ 71.4% | 4.25M▲ 0% |
| Equity Growth % | -35.66% | -50.93% | -68.11% | 13.98% | 109.43% | 74.75% | -73.18% | -49.09% | -71.41% | -259.39% |
| Book Value per Share | 54.54 | 25.17 | 7.69 | 9663.05 | 4246.01 | 2794.36 | 72.96 | 24.17 | 23.45 | 8.82 |
| Total Shareholders' Equity | 59.32M | 29.11M | 9.28M | 10.58M | 22.16M | 38.72M | 10.38M | 5.29M | 1.51M | 4.25M |
| Common Stock | 1.68K | 1.78K | 1.81K | 451 | 2.38K | 4.52K | 225 | 393 | 144 | 94 |
| Retained Earnings | -76.65M | -111.08M | -132.96M | -12.08M | -19.43M | -32.2M | -63.81M | -76.35M | -81.92M | -85.46M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -1.61K | -1.25K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SLRX Cash Flow Statement
Salarius Pharmaceuticals, Inc. (SLRX) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -32.05M | -27.72M | -23.6M | -11.58M | -10.31M | -10.2M | -17.6M | -12.85M | -4.53M | -4.53M |
| Operating CF Margin % | -3171.39% | -2175.14% | -2815.59% | -334.2% | -197.03% | - | - | - | - | - |
| Operating CF Growth % | -54.5% | 13.51% | 14.87% | 50.93% | 10.96% | 1.08% | -72.5% | 26.99% | 64.77% | 61.79% |
| Net Income | -39.49M | -34.43M | -21.92M | -6.94M | -7.35M | -12.77M | -31.61M | -12.54M | -5.58M | -5M |
| Depreciation & Amortization | 277.23K | 324.55K | 228.16K | 127.41K | 18.06K | 19.18K | 6.68K | 10.05K | 4.42K | 4.42K |
| Stock-Based Compensation | 6.57M | 4.22M | 1.94M | 751.62K | 319.39K | 559.04K | 796.8K | 524.84K | 273.73K | 130.58K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 19.59K | -66.36K | 31.85K | -1.31M | -258.55K | -44.69K | 10.84M | 130K | 0 | 0 |
| Working Capital Changes | 571.22K | 2.23M | -3.88M | -4.21M | -3.04M | 2.03M | 2.37M | -968.33K | 772.29K | 436.54K |
| Change in Receivables | 0 | 1.8K | 7.21K | 690 | -3.86M | 2.25M | 0 | 1.48M | 0 | 0 |
| Change in Inventory | 0 | 22.24K | 227.98K | 1.17K | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 309.44K | 819.36K | -1.66M | -519.28K | -2.78K | -310.66K | 1.31M | -2.26M | 334.14K | 798.33K |
| Cash from Investing | -12.24M | 24.49M | 14.12M | 5.61M | -2.6K | 0 | -1.5M | 0 | 0 | -200K |
| Capital Expenditures | -559.38K | -113.5K | 0 | 0 | -2.6K | 0 | 0 | -3 | 0 | 0 |
| CapEx % of Revenue | 55.35% | 8.91% | - | - | 0.05% | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 5.61M | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 5.25K | 5.34K | 4.8K | 0 | 0 | 0 | -1.5M | 3 | 0 | -200K |
| Cash from Financing | 22.1K | 2.63K | 118.01K | 3.58M | 17.69M | 28.3M | 1.99M | 6.64M | 1.06M | 6.16M |
| Debt Issued (Net) | 0 | 0 | 0 | -417.88K | -974.43K | -477.03K | 0 | -280.92K | -466.5K | -328.85K |
| Equity Issued (Net) | 22.1K | 2.63K | 0 | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 626.24K |
| Dividends Paid | 0 | 0 | 0 | -133.59K | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 118.01K | 0 | 3.87M | 1.49M | 0 | 0 | 0 | 5.86M |
| Net Change in Cash | -44.27M▲ 0% | -3.23M▲ 92.7% | -9.36M▼ 189.7% | -2.39M▲ 74.4% | 7.38M▲ 408.4% | 18.1M▲ 145.2% | -17.11M▼ 194.5% | -6.21M▲ 63.7% | -3.47M▲ 44.2% | 1.53M▲ 0% |
| Free Cash Flow | -32.61M▲ 0% | -27.84M▲ 14.6% | -23.6M▲ 15.2% | -11.58M▲ 50.9% | -10.31M▲ 10.9% | -10.2M▲ 1.1% | -19.1M▼ 87.2% | -12.85M▲ 32.7% | -4.53M▲ 64.8% | -4.43M▲ 0% |
| FCF Margin % | -3226.72% | -2184.05% | -2815.59% | -334.2% | -197.08% | - | - | - | - | - |
| FCF Growth % | -55.2% | 14.64% | 15.22% | 50.93% | 10.93% | 1.1% | -87.21% | 32.73% | 64.77% | 16.26% |
| FCF per Share | -29.98 | -24.07 | -19.55 | -10575.61 | -1976.30 | -736.08 | -134.15 | -58.73 | -70.20 | -70.20 |
| FCF Conversion (FCF/Net Income) | 0.81x | 0.81x | 1.08x | 1.67x | 1.40x | 0.80x | 0.56x | 1.02x | 0.81x | 0.89x |
| Interest Paid | 0 | 0 | 0 | 9.01K | 8.66K | 1.47K | 0 | 0 | 0 | 285 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SLRX Key Ratios
Salarius Pharmaceuticals, Inc. (SLRX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -52.13% | -77.88% | -114.21% | -69.84% | -44.91% | -41.94% | -128.73% | -160.07% | -164.02% | -117.81% |
| Return on Invested Capital (ROIC) | -95.87% | -111.25% | -353.26% | -182.39% | -61.92% | -91.41% | -613.37% | - | - | 337.01% |
| Gross Margin | 34.42% | 60.26% | 48.61% | 100% | 100% | - | - | - | - | - |
| Net Margin | -3907.65% | -2701.74% | -2615.57% | -200.18% | -140.49% | - | - | - | - | - |
| Debt / Equity | - | - | - | 0.05x | 0.02x | - | - | 0.05x | 0.15x | 0.15x |
| Interest Coverage | - | - | - | - | -2555.41x | - | - | - | - | - |
| FCF Conversion | 0.81x | 0.81x | 1.08x | 1.67x | 1.40x | 0.80x | 0.56x | 1.02x | 0.81x | 0.89x |
| Revenue Growth | - | 26.11% | -34.24% | 313.42% | 51.03% | -100% | - | - | - | - |
SLRX Frequently Asked Questions
Salarius Pharmaceuticals, Inc. (SLRX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Salarius Pharmaceuticals, Inc. (SLRX) grew revenue by 0.0% over the past year. Growth has been modest.
Salarius Pharmaceuticals, Inc. (SLRX) reported a net loss of $5.0M for fiscal year 2024.
Dividend & Returns
Salarius Pharmaceuticals, Inc. (SLRX) has a return on equity (ROE) of -164.0%. Negative ROE indicates the company is unprofitable.
Salarius Pharmaceuticals, Inc. (SLRX) had negative free cash flow of $4.4M in fiscal year 2024, likely due to heavy capital investments.
Explore More SLRX
Salarius Pharmaceuticals, Inc. (SLRX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates